489 related articles for article (PubMed ID: 25817444)
1. Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.
Dang Q; Li L; Xie H; He D; Chen J; Song W; Chang LS; Chang HC; Yeh S; Chang C
Mol Oncol; 2015 Aug; 9(7):1241-51. PubMed ID: 25817444
[TBL] [Abstract][Full Text] [Related]
2. Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.
Li L; Dang Q; Xie H; Yang Z; He D; Liang L; Song W; Yeh S; Chang C
Oncotarget; 2015 Jun; 6(16):14179-90. PubMed ID: 25895025
[TBL] [Abstract][Full Text] [Related]
3. ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.
Wen S; Tian J; Niu Y; Li L; Yeh S; Chang C
Cancer Lett; 2016 Jul; 376(2):377-86. PubMed ID: 27045473
[TBL] [Abstract][Full Text] [Related]
4. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.
Lin TH; Izumi K; Lee SO; Lin WJ; Yeh S; Chang C
Cell Death Dis; 2013 Aug; 4(8):e764. PubMed ID: 23928703
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
[TBL] [Abstract][Full Text] [Related]
7. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
Lin TH; Lee SO; Niu Y; Xu D; Liang L; Li L; Yeh SD; Fujimoto N; Yeh S; Chang C
J Biol Chem; 2013 Jul; 288(27):19359-69. PubMed ID: 23687298
[TBL] [Abstract][Full Text] [Related]
8. Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression.
Chen J; Li L; Yang Z; Luo J; Yeh S; Chang C
Cancer Lett; 2017 Nov; 408():155-163. PubMed ID: 28826721
[TBL] [Abstract][Full Text] [Related]
9. Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals.
Deng G; Wang R; Sun Y; Huang CP; Yeh S; You B; Feng C; Li G; Ma S; Chang C
Cell Death Differ; 2021 Jul; 28(7):2145-2159. PubMed ID: 34127806
[TBL] [Abstract][Full Text] [Related]
10. ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis.
Niu Y; Guo C; Wen S; Tian J; Luo J; Wang K; Tian H; Yeh S; Chang C
Cancer Lett; 2018 Dec; 439():47-55. PubMed ID: 30227222
[TBL] [Abstract][Full Text] [Related]
11. Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11→miRNA-541→androgen receptor (AR)→MMP9 signaling.
Hu S; Li L; Yeh S; Cui Y; Li X; Chang HC; Jin J; Chang C
Mol Oncol; 2015 Jan; 9(1):44-57. PubMed ID: 25135278
[TBL] [Abstract][Full Text] [Related]
12. Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.
Recouvreux MV; Wu JB; Gao AC; Zonis S; Chesnokova V; Bhowmick N; Chung LW; Melmed S
Endocrinology; 2017 Jul; 158(7):2255-2268. PubMed ID: 28444169
[TBL] [Abstract][Full Text] [Related]
13. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
Wang R; Lin W; Lin C; Li L; Sun Y; Chang C
Cancer Lett; 2016 Aug; 379(1):154-60. PubMed ID: 27233475
[TBL] [Abstract][Full Text] [Related]
14. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells.
Wen S; Niu Y; Lee SO; Yeh S; Shang Z; Gao H; Li Y; Chou F; Chang C
Mol Carcinog; 2016 Dec; 55(12):2278-2290. PubMed ID: 26894509
[TBL] [Abstract][Full Text] [Related]
15. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.
Guerrero J; Alfaro IE; Gómez F; Protter AA; Bernales S
Prostate; 2013 Sep; 73(12):1291-305. PubMed ID: 23765603
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
[TBL] [Abstract][Full Text] [Related]
17. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
[TBL] [Abstract][Full Text] [Related]
18.
Özgür E; Celik AI; Darendeliler E; Gezer U
Anticancer Res; 2017 Jul; 37(7):3631-3637. PubMed ID: 28668854
[TBL] [Abstract][Full Text] [Related]
19. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
20. Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen Enzalutamide sensitivity to better suppress the castration-resistant prostate cancer growth.
Zhang M; Sun Y; Meng J; Zhang L; Liang C; Chang C
Cancer Lett; 2019 Feb; 442():483-490. PubMed ID: 30423407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]